Trending NewsTrending NewsNASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $3.47 -0.87 (-20.05%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.52 +0.05 (+1.44%) As of 08/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GoodRx Stock (NASDAQ:GDRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GoodRx alerts:Sign Up Key Stats Today's Range$3.31▼$4.0050-Day Range$3.47▼$5.0752-Week Range$3.31▼$8.80Volume8.09 million shsAverage Volume1.10 million shsMarket Capitalization$1.24 billionP/E Ratio34.70Dividend YieldN/APrice Target$6.55Consensus RatingModerate Buy Company Overview GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. Read More GoodRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreGDRX MarketRank™: GoodRx scored higher than 62% of companies evaluated by MarketBeat, and ranked 301st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageGoodRx has only been the subject of 2 research reports in the past 90 days.Read more about GoodRx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth38.46% Earnings GrowthEarnings for GoodRx are expected to grow by 38.46% in the coming year, from $0.13 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is 34.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is 34.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 1.93. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.64% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GoodRx has recently increased by 4.15%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.64% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GoodRx has recently increased by 4.15%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment-0.13 News SentimentGoodRx has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GoodRx this week, compared to 5 articles on an average week.Search Interest6 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added GoodRx to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,919.00 in company stock.Percentage Held by InsidersOnly 4.53% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address GDRX Stock News HeadlinesBrokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $6.55August 7 at 2:45 AM | americanbankingnews.comGoodRx shares tumble as Q2 earnings miss expectationsAugust 7 at 2:27 AM | investing.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | Brownstone Research (Ad)What To Expect From GoodRx Holdings Inc (GDRX) Q2 2025 EarningsAugust 7 at 2:27 AM | finance.yahoo.comGoodRx (NASDAQ:GDRX) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock DropsAugust 7 at 2:27 AM | msn.comGoodRx Reports Second Quarter 2025 ResultsAugust 6 at 4:05 PM | businesswire.comGoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To ExpectAugust 6 at 2:58 AM | finance.yahoo.comGoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma SolutionsJuly 28, 2025 | businesswire.comSee More Headlines GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $4.65 at the beginning of the year. Since then, GDRX shares have decreased by 25.4% and is now trading at $3.47. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings data on Wednesday, August, 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.01. The business's quarterly revenue was up 1.2% compared to the same quarter last year. Read the conference call transcript. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (0.47%), Pathway Capital Management LP (0.16%), Assenagon Asset Management S.A. (0.07%) and Allianz Asset Management GmbH (0.07%). Insiders that own company stock include Scott Wagner and Equity Vii LP Spectrum. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryBusiness Services Current SymbolNASDAQ:GDRX CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees950Year FoundedN/APrice Target and Rating Average Price Target for GoodRx$6.55 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+88.6%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.10 Trailing P/E Ratio34.70 Forward P/E Ratio26.69 P/E Growth1.93Net Income$16.39 million Net Margins4.33% Pretax Margin6.00% Return on Equity8.71% Return on Assets4.47% Debt Debt-to-Equity Ratio0.74 Current Ratio5.23 Quick Ratio5.23 Sales & Book Value Annual Sales$792.32 million Price / Sales1.56 Cash Flow$0.25 per share Price / Cash Flow13.64 Book Value$1.89 per share Price / Book1.84Miscellaneous Outstanding Shares357,170,000Free Float340,989,000Market Cap$1.24 billion OptionableOptionable Beta1.24 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:GDRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.